{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:09:32Z","timestamp":1790701772394,"version":"4.1.0"},"reference-count":101,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031315","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Protease activated receptor 2 (PAR2) is a G-protein coupled receptor expressed in meningeal neurons, fibroblasts and mast cells that may be targeted to treat migraine. MEDI0618, a fully humanized PAR2 monoclonal antibody, engineered to enhance FcRn-dependent recycling and currently in clinical development, was evaluated in human and rodent in vitro assays, in multiple murine in vivo migraine models and in a model of post-traumatic headache.<\/jats:p>\n                  <jats:p>MEDI0618 bound specifically and with high affinity to cells expressing human PAR2 (hPAR2) and prevented matriptase-induced increase in cytosolic calcium. Similarly, MEDI0618 prevented matriptase-induced calcium in primary fibroblasts and microvascular endothelial cells from human dura mater. MEDI0618 had no effect on hPAR1 receptors. Single-cell calcium imaging of acutely dissociated mouse trigeminal ganglion neurons confirmed expression and functionality of mouse PAR2. Studies in vivo used evoked cutaneous allodynia as a surrogate of headache-like pain and, in some experiments, rearing as a measure of non-evoked headache pain. MEDI0618 was administered subcutaneously to C57BL6\/J female mice prior to induction of migraine-like pain with (i) systemic nitroglycerin or compound 48\/80 (mast cell degranulator); or (ii) with supradural compound 48\/80 or an inflammatory mediator (IM) cocktail. To assess possible efficacy against CGRP receptor (CGRP-R)-independent pain, MEDI0618 was also evaluated in the IM model in animals pretreated with systemic olcegepant (CGRP-R antagonist). Migraine-like pain was also induced by inhalational umbellulone, a TRPA1 agonist, in animals primed with restraint stress in the presence or absence of MEDI0618 as well as in a model of post-traumatic headache pain induced by a mild traumatic brain injury.<\/jats:p>\n                  <jats:p>MEDI0618 prevented cutaneous allodynia elicited by systemic nitroglycerin, compound 48\/80 and from supradural compound 48\/80 and IM. Systemic olcegepant completely blocked periorbital cutaneous allodynia induced by supradural CGRP but failed to reduce IM-induced cutaneous allodynia. In contrast, MEDI0618 fully prevented IM-induced cutaneous allodynia, regardless of pretreatment with olcegepant. Umbellulone elicited cutaneous allodynia only in restraint stress-primed animals, which was prevented by MEDI0618. MEDI0618 prevented the decrease in rearing behaviour elicited by compound 48\/80. However, MEDI0618 did not prevent mild traumatic brain injury-related post-traumatic headache measures.<\/jats:p>\n                  <jats:p>These data indicate that MEDI0618 is a potent and selective inhibitor of PAR2 that is effective in human and rodent in vitro cell systems. Further, blockade of PAR2 with MEDI0618 was effective in all preclinical migraine models studied but not in a model of post-traumatic headache. MEDI0618 may represent a novel therapy for migraine prevention with activity against CGRP-dependent and independent attacks.<\/jats:p>","DOI":"10.1093\/brain\/awae344","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T09:39:37Z","timestamp":1730281177000},"page":"1345-1359","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine"],"prefix":"10.1093","volume":"148","author":[{"given":"Caroline M","family":"Kopruszinski","sequence":"first","affiliation":[{"name":"Department of Pharmacology, College of Medicine, University of Arizona , Tucson, AZ 85724 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6450-8805","authenticated-orcid":false,"given":"John E","family":"Linley","sequence":"additional","affiliation":[{"name":"Neuroscience, BioPharmaceutical R&D, AstraZeneca , Cambridge, CB2 0AA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Thornton","sequence":"additional","affiliation":[{"name":"Neuroscience, BioPharmaceutical R&D, AstraZeneca , Cambridge, CB2 0AA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison S","family":"Walker","sequence":"additional","affiliation":[{"name":"Neuroscience, BioPharmaceutical R&D, AstraZeneca , Cambridge, CB2 0AA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Newton","sequence":"additional","affiliation":[{"name":"Discovery Sciences, AstraZeneca , Cambridge, CB2 0AA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhana","family":"Podichetty","sequence":"additional","affiliation":[{"name":"Discovery Sciences, AstraZeneca , Cambridge, CB2 0AA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhey Hemendra","family":"Ruparel","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Medicine, University of Arizona , Tucson, AZ 85724 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Henrique","family":"Moreira de Souza","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Medicine, University of Arizona , Tucson, AZ 85724 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edita","family":"Navratilova","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Medicine, University of Arizona , Tucson, AZ 85724 ,","place":["USA"]},{"name":"Department of Neurology, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Meno-Tetang","sequence":"additional","affiliation":[{"name":"Neuroscience, BioPharmaceutical R&D, AstraZeneca , Cambridge, CB2 0AA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Gurrell","sequence":"additional","affiliation":[{"name":"Neuroscience, BioPharmaceutical R&D, AstraZeneca , Cambridge, CB2 0AA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Dodick","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]},{"name":"Atria Academy of Science and Medicine , New York, NY 10022 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dobson","sequence":"additional","affiliation":[{"name":"Discovery Sciences, AstraZeneca , Cambridge, CB2 0AA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharani","family":"Chessell","sequence":"additional","affiliation":[{"name":"Neuroscience, BioPharmaceutical R&D, AstraZeneca , Cambridge, CB2 0AA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Porreca","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Medicine, University of Arizona , Tucson, AZ 85724 ,","place":["USA"]},{"name":"Department of Neurology, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Chessell","sequence":"additional","affiliation":[{"name":"Neuroscience, BioPharmaceutical R&D, AstraZeneca , Cambridge, CB2 0AA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"2025040317001154000_awae344-B1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11910-022-01175-w","article-title":"Post-traumatic headache: Pharmacologic management and targeting CGRP signaling","volume":"22","author":"Ashina","year":"2022","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2025040317001154000_awae344-B2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","article-title":"Diagnosis and management of migraine in ten steps","volume":"17","author":"Eigenbrodt","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"2025040317001154000_awae344-B3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","article-title":"Migraine","volume":"8","author":"Ferrari","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2025040317001154000_awae344-B4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.11607\/ofph.3163","article-title":"Novel migraine treatments: A review","volume":"37","author":"George","year":"2023","journal-title":"J Oral Facial Pain Headache"},{"key":"2025040317001154000_awae344-B5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s10194-022-01398-9","article-title":"Post-traumatic headache after mild traumatic brain injury in a one-year follow up study\u2014Risk factors and return to work","volume":"23","author":"Kraemer","year":"2022","journal-title":"J Headache Pain"},{"key":"2025040317001154000_awae344-B6","doi-asserted-by":"crossref","first-page":"E187","DOI":"10.1503\/cmaj.221607","article-title":"Pharmacologic prevention of migraine","volume":"195","author":"Tzankova","year":"2023","journal-title":"CMAJ"},{"key":"2025040317001154000_awae344-B7","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102420941839","article-title":"Guidelines of the international headache society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults","volume":"40","author":"Diener","year":"2020","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","article-title":"CGRP monoclonal antibodies in migraine: An efficacy and tolerability comparison with standard prophylactic drugs","volume":"22","author":"Vandervorst","year":"2021","journal-title":"J Headache Pain"},{"key":"2025040317001154000_awae344-B9","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","article-title":"Targeting calcitonin gene-related peptide: A new era in migraine therapy","volume":"394","author":"Charles","year":"2019","journal-title":"Lancet"},{"key":"2025040317001154000_awae344-B10","doi-asserted-by":"crossref","first-page":"107528","DOI":"10.1016\/j.pharmthera.2020.107528","article-title":"Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans","volume":"211","author":"de Vries","year":"2020","journal-title":"Pharmacol Ther"},{"key":"2025040317001154000_awae344-B11","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.3390\/ijms20143527","article-title":"Effects of anti-calcitonin gene-related peptide for migraines: A systematic review with meta-analysis of randomized clinical trials","volume":"20","author":"Huang","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025040317001154000_awae344-B12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s10194-023-01539-8","article-title":"The sense of stopping migraine prophylaxis","volume":"24","author":"Al-Hassany","year":"2023","journal-title":"J Headache Pain"},{"key":"2025040317001154000_awae344-B13","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/ene.15260","article-title":"Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine","volume":"29","author":"Iannone","year":"2022","journal-title":"Eur J Neurol"},{"key":"2025040317001154000_awae344-B14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/03331024211046617","article-title":"Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: A prospective, longitudinal cohort study","volume":"42","author":"Raffaelli","year":"2022","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","article-title":"Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: An observational longitudinal cohort study","volume":"22","author":"Vernieri","year":"2021","journal-title":"J Headache Pain"},{"key":"2025040317001154000_awae344-B16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s13760-016-0645-y","article-title":"Allergens might trigger migraine attacks","volume":"117","author":"Bektas","year":"2017","journal-title":"Acta Neurol Belg"},{"key":"2025040317001154000_awae344-B17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1081-1206(10)60018-X","article-title":"Prevalence of migraine headaches in patients with allergic rhinitis","volume":"97","author":"Ku","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025040317001154000_awae344-B18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1017\/S1092852900018745","article-title":"The comorbidity of migraine","volume":"8","author":"Low","year":"2003","journal-title":"CNS Spectr"},{"key":"2025040317001154000_awae344-B19","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1097\/j.pain.0000000000001531","article-title":"Migraine understood as a sensory threshold disease","volume":"160","author":"Peng","year":"2019","journal-title":"Pain"},{"key":"2025040317001154000_awae344-B20","doi-asserted-by":"crossref","first-page":"29069","DOI":"10.3390\/ijms161226151","article-title":"Mast cell-mediated mechanisms of nociception","volume":"16","author":"Aich","year":"2015","journal-title":"Int J Mol Sci"},{"key":"2025040317001154000_awae344-B21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3389\/fnins.2017.00703","article-title":"Mast cell activation in brain injury, stress, and post-traumatic stress disorder and Alzheimer's disease pathogenesis","volume":"11","author":"Kempuraj","year":"2017","journal-title":"Front Neurosci"},{"key":"2025040317001154000_awae344-B22","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.pain.2007.03.012","article-title":"Mast cell degranulation activates a pain pathway underlying migraine headache","volume":"130","author":"Levy","year":"2007","journal-title":"Pain"},{"key":"2025040317001154000_awae344-B23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbadis.2010.12.014","article-title":"Mast cells and inflammation","volume":"1822","author":"Theoharides","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2025040317001154000_awae344-B24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.brainresrev.2004.11.006","article-title":"The role of mast cells in migraine pathophysiology","volume":"49","author":"Theoharides","year":"2005","journal-title":"Brain Res Brain Res Rev"},{"key":"2025040317001154000_awae344-B25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728222.2014.844792","article-title":"Protease-activated receptor 2 signalling pathways: A role in pain processing","volume":"18","author":"Bao","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"2025040317001154000_awae344-B26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.33549\/physiolres.933269","article-title":"The role of protease-activated receptor type 2 in nociceptive signaling and pain","volume":"65","author":"Mrozkova","year":"2016","journal-title":"Physiol Res"},{"key":"2025040317001154000_awae344-B27","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1526-4610.2010.01679.x","article-title":"Activation of PAR-2 elicits NO-dependent and CGRP-independent dilation of the dural artery","volume":"50","author":"Bhatt","year":"2010","journal-title":"Headache"},{"key":"2025040317001154000_awae344-B28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/0333102418779548","article-title":"Protease activated receptor 2 (PAR2) activation causes migraine-like pain behaviors in mice","volume":"39","author":"Hassler","year":"2019","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B29","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1177\/0333102420966581","article-title":"Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine","volume":"40","author":"Kopruszinski","year":"2020","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s10194-023-01574-5","article-title":"PAR2 activation in the dura causes acute behavioral responses and priming to glyceryl trinitrate in a mouse migraine model","volume":"24","author":"Mason","year":"2023","journal-title":"J Headache Pain"},{"key":"2025040317001154000_awae344-B31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pain.2006.05.007","article-title":"PAR-2 agonists activate trigeminal nociceptors and induce functional competence in the delta opioid receptor","volume":"125","author":"Patwardhan","year":"2006","journal-title":"Pain"},{"key":"2025040317001154000_awae344-B32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1468-2982.2007.01523.x","article-title":"Modulation of meningeal nociceptors mechanosensitivity by peripheral proteinase-activated receptor-2: The role of mast cells","volume":"28","author":"Zhang","year":"2008","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B33","doi-asserted-by":"crossref","first-page":"4243953","DOI":"10.1155\/2020\/4243953","article-title":"Mast cell activation, neuroinflammation, and tight junction protein derangement in acute traumatic brain injury","volume":"2020","author":"Kempuraj","year":"2020","journal-title":"Mediators Inflamm"},{"key":"2025040317001154000_awae344-B34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/0333102415617412","article-title":"Responses of dural mast cells in concussive and blast models of mild traumatic brain injury in mice: Potential implications for post-traumatic headache","volume":"36","author":"Levy","year":"2016","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nprot.2006.461","article-title":"Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity","volume":"2","author":"Malin","year":"2007","journal-title":"Nat Protoc"},{"key":"2025040317001154000_awae344-B36","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jmb.2007.12.018","article-title":"The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies","volume":"376","author":"Rothe","year":"2008","journal-title":"J Mol Biol"},{"key":"2025040317001154000_awae344-B37","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/0022-2836(92)90639-2","article-title":"Selection of phage antibodies by binding affinity. Mimicking affinity maturation","volume":"226","author":"Hawkins","year":"1992","journal-title":"J Mol Biol"},{"key":"2025040317001154000_awae344-B38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/0333102418779557","article-title":"Non-invasive dural stimulation in mice: A novel preclinical model of migraine","volume":"39","author":"Burgos-Vega","year":"2019","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B39","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1152\/jn.00970.2014","article-title":"Repetitive mild traumatic brain injury induces ventriculomegaly and cortical thinning in juvenile rats","volume":"113","author":"Goddeyne","year":"2015","journal-title":"J Neurophysiol"},{"key":"2025040317001154000_awae344-B40","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/0333102420981688","article-title":"CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache","volume":"41","author":"Kopruszinski","year":"2021","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B41","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1177\/0333102419877662","article-title":"CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice","volume":"39","author":"Navratilova","year":"2019","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1179\/2042618613Y.0000000053","article-title":"Chronic post-traumatic headache: Clinical findings and possible mechanisms","volume":"22","author":"Defrin","year":"2014","journal-title":"J Man Manip Ther."},{"key":"2025040317001154000_awae344-B43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11916-010-0117-7","article-title":"Posttraumatic headache: A review","volume":"14","author":"Seifert","year":"2010","journal-title":"Curr Pain Headache Rep"},{"key":"2025040317001154000_awae344-B44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0333102420959794","article-title":"A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain","volume":"41","author":"Kopruszinski","year":"2020","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B45","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.pain.2012.06.012","article-title":"Activation of TRPA1 on dural afferents: A potential mechanism of headache pain","volume":"153","author":"Edelmayer","year":"2012","journal-title":"Pain"},{"key":"2025040317001154000_awae344-B46","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1468-2982.2004.00781.x","article-title":"Cephalic venous congestion aggravates only migraine-type headaches","volume":"24","author":"Chou","year":"2004","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1468-2982.2008.01746.x","article-title":"Throbbing pain is related to queckenstedt's test effect in migraine patients","volume":"29","author":"Chou","year":"2009","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B48","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1526-4610.2009.01443.x","article-title":"Migraine and the environment","volume":"49","author":"Friedman","year":"2009","journal-title":"Headache"},{"key":"2025040317001154000_awae344-B49","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1523\/JNEUROSCI.2967-16.2016","article-title":"Induction of migraine-like photophobic behavior in mice by both peripheral and central CGRP mechanisms","volume":"37","author":"Mason","year":"2017","journal-title":"J Neurosci"},{"issue":"6 Suppl 1","key":"2025040317001154000_awae344-B50","first-page":"S20","article-title":"Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability","volume":"56","author":"Stewart","year":"2001","journal-title":"Neurology"},{"key":"2025040317001154000_awae344-B51","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.neulet.2017.04.059","article-title":"Behavioral study of a rat model of migraine induced by CGRP","volume":"651","author":"Yao","year":"2017","journal-title":"Neurosci Lett"},{"key":"2025040317001154000_awae344-B52","doi-asserted-by":"crossref","first-page":"C1429","DOI":"10.1152\/ajpcell.1998.274.6.C1429","article-title":"Proteinase-activated receptors: Novel mechanisms of signaling by serine proteases","volume":"274","author":"Dery","year":"1998","journal-title":"Am J Physiol"},{"key":"2025040317001154000_awae344-B53","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1124\/pr.54.2.203","article-title":"International union of pharmacology. XXVIII. Proteinase-activated receptors","volume":"54","author":"Hollenberg","year":"2002","journal-title":"Pharmacol Rev"},{"key":"2025040317001154000_awae344-B54","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/89945","article-title":"Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway","volume":"7","author":"Vergnolle","year":"2001","journal-title":"Nat Med"},{"key":"2025040317001154000_awae344-B55","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0165-6147(00)01634-5","article-title":"Protease-activated receptors in inflammation, neuronal signaling and pain","volume":"22","author":"Vergnolle","year":"2001","journal-title":"Trends Pharmacol Sci"},{"key":"2025040317001154000_awae344-B56","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nbt.1691","article-title":"Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization","volume":"28","author":"Igawa","year":"2010","journal-title":"Nat Biotechnol"},{"key":"2025040317001154000_awae344-B57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12959-019-0194-8","article-title":"Protease-activated receptors (PARs): Mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases","volume":"17","author":"Heuberger","year":"2019","journal-title":"Thromb J"},{"key":"2025040317001154000_awae344-B58","doi-asserted-by":"crossref","first-page":"19076","DOI":"10.1074\/jbc.M110.185264","article-title":"The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo","volume":"286","author":"Flynn","year":"2011","journal-title":"J Biol Chem"},{"key":"2025040317001154000_awae344-B59","first-page":"e137393","article-title":"The cellular basis of protease-activated receptor 2-evoked mechanical and affective pain","volume":"5","author":"Hassler","year":"2020","journal-title":"JCI Insight"},{"issue":"Suppl 1","key":"2025040317001154000_awae344-B60","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-2006-939553","article-title":"Protease-activated receptors: How proteases signal to cells to cause inflammation and pain","volume":"32","author":"Bunnett","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"2025040317001154000_awae344-B61","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.neuroscience.2011.06.085","article-title":"Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain","volume":"193","author":"Chen","year":"2011","journal-title":"Neuroscience"},{"key":"2025040317001154000_awae344-B62","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI30951","article-title":"Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain","volume":"117","author":"Dai","year":"2007","journal-title":"J Clin Invest"},{"issue":"Pt 3","key":"2025040317001154000_awae344-B63","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1113\/jphysiol.2006.121111","article-title":"Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice","volume":"578","author":"Grant","year":"2007","journal-title":"J Physiol"},{"key":"2025040317001154000_awae344-B64","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jpain.2022.11.006","article-title":"C781, a beta-arrestin biased antagonist at protease-activated receptor-2 (PAR2), displays in vivo efficacy against protease-induced pain in mice","volume":"24","author":"Kume","year":"2023","journal-title":"J Pain"},{"key":"2025040317001154000_awae344-B65","doi-asserted-by":"crossref","first-page":"100028","DOI":"10.1016\/j.ynpai.2019.100028","article-title":"Cyclic nucleotide signaling in sensory neuron hyperexcitability and chronic pain after nerve injury","volume":"6","author":"Li","year":"2019","journal-title":"Neurobiol Pain"},{"issue":"Pt 6","key":"2025040317001154000_awae344-B66","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1042\/bst0311191","article-title":"Protease-activated receptor 2: Activation, signalling and function","volume":"31","author":"Cottrell","year":"2003","journal-title":"Biochem Soc Trans"},{"key":"2025040317001154000_awae344-B67","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0306-4522(96)00488-5","article-title":"Functional relationships between sensory nerve fibers and mast cells of dura mater in normal and inflammatory conditions","volume":"77","author":"Dimitriadou","year":"1997","journal-title":"Neuroscience"},{"key":"2025040317001154000_awae344-B68","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s10194-021-01353-0","article-title":"Parenchymal neuroinflammatory signaling and dural neurogenic inflammation in migraine","volume":"22","author":"Erdener","year":"2021","journal-title":"J Headache Pain"},{"key":"2025040317001154000_awae344-B69","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1177\/0333102417740563","article-title":"Human mast cells release the migraine-inducing factor pituitary adenylate cyclase-activating polypeptide (PACAP)","volume":"38","author":"Okragly","year":"2018","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B70","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/imr.12622","article-title":"Mast cell-neural interactions contribute to pain and itch","volume":"282","author":"Gupta","year":"2018","journal-title":"Immunol Rev"},{"issue":"3 Suppl","key":"2025040317001154000_awae344-B71","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1111\/1523-1747.ep12468899","article-title":"Systemic mastocytosis: Retrospective review of a decade's clinical experience at the Brigham and Women's Hospital","volume":"96","author":"Horan","year":"1991","journal-title":"J Invest Dermatol"},{"key":"2025040317001154000_awae344-B72","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1177\/0333102411421683","article-title":"Primary headache syndromes in systemic mastocytosis","volume":"31","author":"Smith","year":"2011","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B73","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/WNL.39.9.1239","article-title":"Serotonin metabolism in migraine","volume":"39","author":"Ferrari","year":"1989","journal-title":"Neurology"},{"key":"2025040317001154000_awae344-B74","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2222.1982.tb01633.x","article-title":"Increased plasma histamine levels in migraine patients","volume":"12","author":"Heatley","year":"1982","journal-title":"Clin Allergy"},{"key":"2025040317001154000_awae344-B75","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1526-4610.1999.3902101.x","article-title":"Mast cell activation in children with migraine before and after training in self-regulation","volume":"39","author":"Olness","year":"1999","journal-title":"Headache"},{"key":"2025040317001154000_awae344-B76","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000229382","article-title":"The activation of mast cells by the histamine liberator 48\/80 in man","volume":"22","author":"Sicuteri","year":"1963","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"2025040317001154000_awae344-B77","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1096\/fj.11-201004","article-title":"An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats","volume":"26","author":"Lohman","year":"2012","journal-title":"FASEB J"},{"key":"2025040317001154000_awae344-B78","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1476-5381.2011.01610.x","article-title":"Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110)","volume":"165","author":"Suen","year":"2012","journal-title":"Br J Pharmacol"},{"key":"2025040317001154000_awae344-B79","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00281-018-0676-y","article-title":"Neurogenic inflammation and its role in migraine","volume":"40","author":"Ramachandran","year":"2018","journal-title":"Semin Immunopathol"},{"key":"2025040317001154000_awae344-B80","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1177\/0333102420910114","article-title":"Headache and non-headache symptoms provoked by nitroglycerin in migraineurs: A human pharmacological triggering study","volume":"40","author":"Karsan","year":"2020","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B81","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.nurt.2010.03.006","article-title":"Nitric oxide-related drug targets in headache","volume":"7","author":"Olesen","year":"2010","journal-title":"Neurotherapeutics"},{"key":"2025040317001154000_awae344-B82","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s10194-019-0963-6","article-title":"Behavioral and cognitive animal models in headache research","volume":"20","author":"Vuralli","year":"2019","journal-title":"J Headache Pain"},{"key":"2025040317001154000_awae344-B83","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1113\/EP086092","article-title":"Activation of protease-activated receptor 2 mediates cutaneous vasodilatation but not sweating: Roles of nitric oxide synthase and cyclo-oxygenase","volume":"102","author":"Fujii","year":"2017","journal-title":"Exp Physiol"},{"key":"2025040317001154000_awae344-B84","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1523\/JNEUROSCI.1366-22.2023","article-title":"Peroxynitrite contributes to behavioral responses, increased trigeminal excitability, and changes in mitochondrial function in a preclinical model of migraine","volume":"43","author":"Lackovic","year":"2023","journal-title":"J Neurosci"},{"key":"2025040317001154000_awae344-B85","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4103\/0972-2327.182302","article-title":"Understanding migraine: Potential role of neurogenic inflammation","volume":"19","author":"Malhotra","year":"2016","journal-title":"Ann Indian Acad Neurol"},{"key":"2025040317001154000_awae344-B86","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.3390\/biomedicines10123175","article-title":"Estradiol treatment enhances behavioral and molecular changes induced by repetitive trigeminal activation in a rat model of migraine","volume":"10","author":"Spekker","year":"2022","journal-title":"Biomedicines"},{"key":"2025040317001154000_awae344-B87","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1021\/cn500083e","article-title":"Targeting TRP channels for novel migraine therapeutics","volume":"5","author":"Dussor","year":"2014","journal-title":"ACS Chem Neurosci"},{"key":"2025040317001154000_awae344-B88","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pain.2010.08.021","article-title":"TRPA1 receptors mediate environmental irritant-induced meningeal vasodilatation","volume":"152","author":"Kunkler","year":"2011","journal-title":"Pain"},{"issue":"Pt 2","key":"2025040317001154000_awae344-B89","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/brain\/awr272","article-title":"The \u2018headache tree\u2019 via umbellulone and TRPA1 activates the trigeminovascular system","volume":"135","author":"Nassini","year":"2012","journal-title":"Brain"},{"key":"2025040317001154000_awae344-B90","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1523\/JNEUROSCI.5679-03.2004","article-title":"Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia","volume":"24","author":"Amadesi","year":"2004","journal-title":"J Neurosci"},{"issue":"Pt 2","key":"2025040317001154000_awae344-B91","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1113\/jphysiol.2006.111534","article-title":"Protease-activated receptor 2 sensitizes TRPV1 by protein kinase cepsilon- and A-dependent mechanisms in rats and mice","volume":"575","author":"Amadesi","year":"2006","journal-title":"J Physiol"},{"key":"2025040317001154000_awae344-B92","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1523\/JNEUROSCI.0454-04.2004","article-title":"Proteinase-activated receptor 2-mediated potentiation of transient receptor potential vanilloid subfamily 1 activity reveals a mechanism for proteinase-induced inflammatory pain","volume":"24","author":"Dai","year":"2004","journal-title":"J Neurosci"},{"issue":"Pt 2","key":"2025040317001154000_awae344-B93","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1113\/jphysiol.2002.032011","article-title":"Mast cell tryptase and proteinase-activated receptor 2 induce hyperexcitability of Guinea-pig submucosal neurons","volume":"547","author":"Reed","year":"2003","journal-title":"J Physiol"},{"key":"2025040317001154000_awae344-B94","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41582-019-0243-8","article-title":"Post-traumatic headache: Epidemiology and pathophysiological insights","volume":"15","author":"Ashina","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"2025040317001154000_awae344-B95","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11916-021-00970-3","article-title":"Models for treating post-traumatic headache","volume":"25","author":"Kamins","year":"2021","journal-title":"Curr Pain Headache Rep"},{"key":"2025040317001154000_awae344-B96","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/0333102421991819","article-title":"Distinguishing persistent post-traumatic headache from migraine: Classification based on clinical symptoms and brain structural MRI data","volume":"41","author":"Chong","year":"2021","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B97","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/0333102418815650","article-title":"Differences in fibertract profiles between patients with migraine and those with persistent post-traumatic headache","volume":"39","author":"Chong","year":"2019","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B98","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s10194-017-0796-0","article-title":"Persistent post-traumatic headache vs. Migraine: An MRI study demonstrating differences in brain structure","volume":"18","author":"Schwedt","year":"2017","journal-title":"J Headache Pain"},{"key":"2025040317001154000_awae344-B99","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1177\/0333102419847728","article-title":"Static and dynamic functional connectivity differences between migraine and persistent post-traumatic headache: A resting-state magnetic resonance imaging study","volume":"39","author":"Dumkrieger","year":"2019","journal-title":"Cephalalgia"},{"key":"2025040317001154000_awae344-B100","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1093\/brain\/awac040","article-title":"The PACAP pathway is independent of CGRP in mouse models of migraine: Possible new drug target?","volume":"145","author":"Ernstsen","year":"2022","journal-title":"Brain"},{"key":"2025040317001154000_awae344-B101","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s10194-022-01523-8","article-title":"PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine","volume":"23","author":"Guo","year":"2022","journal-title":"J Headache Pain"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awae344\/62201734\/awae344.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/4\/1345\/62201734\/awae344.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/4\/1345\/62201734\/awae344.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T18:58:39Z","timestamp":1743706719000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/148\/4\/1345\/8045723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":101,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,28]]},"published-print":{"date-parts":[[2025,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awae344","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,2,28]]}}}